• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

YQ128

CAS No. 2454246-18-3

YQ128 ( —— )

产品货号. M26514 CAS No. 2454246-18-3

YQ128是第二代NLRP3(NOD样受体P3)炎症小体的有效选择性抑制剂(IC50为0.30 μM),具有抗炎活性。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥988 有现货
10MG ¥1596 有现货
25MG ¥2608 有现货
50MG ¥4358 有现货
100MG ¥6294 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    YQ128
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    YQ128是第二代NLRP3(NOD样受体P3)炎症小体的有效选择性抑制剂(IC50为0.30 μM),具有抗炎活性。
  • 产品描述
    YQ128 is a potent and selective inhibitor of second-generation NLRP3 (NOD-like receptor P3) inflammasome(IC50 of 0.30 μM), with anti-inflammatory activity.(In Vitro):The release of IL-1β from peritoneal macrophages upon LPS/ATP challenge(IC50 of 1.59 μM) dose dependently suppressed by YQ128 (0.3-100 μM; 30 mins). (In Vivo):YQ128 (oral; 20 mg/kg) shows delayed gastrointestinal absorption with a tmax and cmax of 12 h and 73 ng/mL, respectively. YQ128 exhibits extensive extravascular distribution with a large steady-state volume of distribution (Vdss) of 8.5 L/kg and rapid total clearance (CLtot) of 41 mL/min/kg. In C57BL/6 mice, YQ128 (10 mg/kg) has been shown to trigger IL-1β production in a NLRP3- dependent manner .
  • 体外实验
    YQ128 (0.3-100 μM; 30 mins) dose dependently suppressed the release of IL-1β from peritoneal macrophages upon LPS/ATP challenge with an IC50 of 1.59 μM. YQ128 (20 μM; 2 hours) shows no significant toxic effects on hCMEC/D3 cells. Cell Viability Assay Cell Line:Mouse peritoneal macrophages Concentration:0.3, 1.0, 3.0, 10, 30, 100 μM Incubation Time:30 mins Result:Suppressed the release of IL-1β from peritoneal macrophages upon LPS/ATP challenge with an IC50 of 1.59 μM.
  • 体内实验
    YQ128 (iv; 20 mg/kg) has an intermediate terminal plasma half-life (t1/2) of 6.6 hours after iv administration. YQ128 (oral; 20 mg/kg) shows delayed gastrointestinal absorption with a tmax and cmax of 12 h and 73 ng/mL, respectively. Oral bioavailability (Foral) is estimated as 10%. YQ128 exhibits extensive extravascular distribution with a large steady-state volume of distribution (Vdss) of 8.5 L/kg and rapid total clearance (CLtot) of 41 mL/min/kg. YQ128 (10 mg/kg) has been shown to trigger IL-1β production in a NLRP3- dependent manner in C57BL/6 mice. Animal Model:Sprague-Dawley rats (200-250 g)Dosage:20 mg/kg (Pharmacokinetic Analysis)Administration:Iv Result:Had an intermediate terminal plasma half-life (t1/2) of 6.6 hours after iv administration.
  • 同义词
    ——
  • 通路
    Apoptosis
  • 靶点
    IL Receptor
  • 受体
    M5 mAChR
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    2454246-18-3
  • 分子量
    545.11
  • 分子式
    C27H29ClN2O4S2
  • 纯度
    >98% (HPLC)
  • 溶解度
    In Vitro:?DMSO : 250 mg/mL (458.62 mM)
  • SMILES
    CCCOc1ccc(Cl)cc1CN(CCc1ccc(cc1)S(=O)(=O)NCC#C)C(=O)Cc1ccsc1
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1.Bridges TM, et al. Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5617-22.
产品手册
关联产品
  • Rolinsatamab

    Rolinsatamab 是一种有效的 IL-4 和 IL-13 双重抑制剂,是一种完全人源化的双特异性单克隆抗体。Rolinsatamab 嵌合抗原受体序列 T 细胞。Rolinsatamab 可用于免疫疾病的研究。

  • Sarilumab

    Sarilumab (SAR-153191)is a potent interleukin-6 IL-6 receptor antagonist and a human immunoglobulin G1 monoclonal antibody. Sarilumab inhibits IL-6-mediated signaling and reduces inflammation.Sarilumab is used for the prevention and treatment of rheumatoid arthritis.

  • Suplatast tosilate

    一种 Th2 细胞因子抑制剂,可减弱 IL-2、IL-5 和 IL-13 的产生,但对 IFN-γ 的产生没有影响。